If you or a loved one has been prescribed Lupron Depot®, we can help you better understand the treatment and how it works.

Lupron Depot belongs to a class of drugs called gonadotropin-releasing hormone (GnRH) agonists. It is used to decrease the body's production of specific hormones, natural chemicals that influence the behavior of certain cells. Because Lupron Depot can reduce the production of both male and female hormones, it is used to treat specific conditions in men, women, and children.

This site provides information on several conditions including fibroids, prostate cancer, endometriosis, and central precocious puberty.

To find out more about Lupron Depot therapy, click on the specific condition that interests you.
 
 
 
 
Healthcare Professionals

Please see below for important information on Lupron Depot, including side effects.
Contact TAP | Terms of Use | Privacy Policy

 

PROSTATE CANCER: Lupron Depot (-4 Month 30 mg, -3 Month 22.5 mg, and 7.5 mg) is indicated for the palliative treatment of advanced prostate cancer. The most common side effect associated with Lupron Depot® is hot flashes. Like other treatment options, GnRH agonists may cause impotence. Symptoms may worsen over the first few weeks of treatment. Periodic monitoring of PSA and serum testosterone levels is recommended. The -4 Month 30 mg, -3 Month 22.5 mg, and 7.5 mg dosage forms are not indicated for use in women. For further information, please see the complete prescribing information.

ENDOMETRIOSIS: Lupron Depot (3.75 mg and -3 Month 11.25 mg) is indicated in the treatment of endometriosis. Side effects are generally those related to hypoestrogenism, including vasomotor flushes, headaches, and vaginal dryness. After six months of therapy with Lupron Depot® 3.75 mg, vertebral bone density decreased by an average of 3.2%, compared with the pretreatment value. For further information, please see the complete prescribing information.

FIBROIDS: Lupron Depot (3.75 mg and -3 Month 11.25 mg), in combination with iron, is indicated for the preoperative treatment of anemia associated with uterine fibroids. Most common side effects with Lupron Depot® are generally those related to hypoestrogenism, including vasomotor flushes, headaches, and vaginal dryness. A small amount of bone loss (average 2.7% at month 3) may also occur during therapy. For further information, please see the complete prescribing information.

CENTRAL PRECOCIOUS PUBERTY: Lupron Depot-PED® (7.5 mg, 11.25 mg, and 15 mg) is indicated in the treatment of central precocious puberty. In clinical studies, the most frequent adverse event related to therapy with Lupron Depot-PED was an injection site reaction, seen in 5% of children in the combined studies. The recommended starting dose of Lupron Depot-PED is 0.3 mg/kg/4 weeks (minimum 7.5 mg). Inadequate dosing may result in poor control of the pubertal process. For further information, please see the complete prescribing information.

  
This site is intended for U.S. audiences only.
© 2004 TAP Pharmaceutical Products Inc. All rights reserved.